Clinical Trials

304 enrolled

Lung Neoplasms

NCT06731907 2026-05-26

MK-3475-01G

90 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06312176 2026-05-22

MK-2870-010

1,200 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06704724 2026-05-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Phase 1 Terminated

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06841354 2026-05-22

TroFuse-011

1,000 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT06998940 2026-05-22

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

94 enrolled

Pancreatic Neoplasms

NCT07060807 2026-05-22

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

1,000 enrolled

Breast Neoplasms

NCT07601737 2026-05-22

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

182 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05431270 2026-05-19

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

40 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

61 enrolled

Phase 1/2 Active not recruiting

Metastatic Pancreatic Ductal Adenocarcinoma

NCT07280377 2026-05-19

GOBLET

122 enrolled

Anal Cancer Metastatic

NCT03279237 2026-05-18

A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

Phase 1 Completed

25 enrolled 9 charts

GastroEsophageal Cancer

NCT04165070 2026-05-18

MK-3475-01A

450 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05685602 2026-05-18

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Phase 1 Suspended

43 enrolled

Pancreatic Neoplasms

NCT07394387 2026-05-15

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

58 enrolled

Triple Negative Breast Neoplasms

NCT04589234 2026-05-14

Saltikva for Metastatic Pancreatic Cancer

60 enrolled

Pancreatic Neoplasms

NCT03606967 2026-05-13

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

70 enrolled

Triple Negative Breast Neoplasms

NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

115 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04310007 2026-05-13

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

117 enrolled

Lung Neoplasms

NCT05422794 2026-05-13

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Phase 1 Recruiting

57 enrolled

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07578337 2026-05-13

NUMANTIA-2

40 enrolled

Neoplasms, Pancreatic Neoplasms

NCT03415854 2026-05-12

NABPLAGEMD

Phase 2 Completed

34 enrolled 11 charts

Adenocarcinoma, Pancreatic Neoplasms

NCT04251533 2026-05-11

EPIK-B3

Phase 3 Terminated

137 enrolled 21 charts

Phase 1 Active not recruiting

Triple Negative Breast Neoplasms

NCT04104672 2026-05-07

ARC-8

196 enrolled

Pancreatic Neoplasms

NCT02270814 2026-05-05

CACTUX

74 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04233866 2026-05-05

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

176 enrolled

Pancreatic Neoplasms

NCT04266249 2026-05-05

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

2,175 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT04481204 2026-05-04

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Phase 2 Withdrawn

Borderline Resectable Pancreatic Adenocarcinoma

NCT05624996 2026-05-04

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

474 enrolled

Lung Neoplasms

NCT06958328 2026-05-04

LAP100

356 enrolled

Pancreatic Neoplasms

NCT05358548 2026-04-30

ATATcH Alternating Treatment Plans for Advanced Cancer

150 enrolled

Head & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms

NCT06390059 2026-04-30

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Completed

84 enrolled

Pancreatic Neoplasms

NCT07076121 2026-04-30

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Phase 2/3 Recruiting

470 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT02495896 2026-04-29

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

61 enrolled

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Pancreatic Neoplasms

NCT06483555 2026-04-23

PANGEA

DermatologicGastrointestinal

104 enrolled

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT07547332 2026-04-23

Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC

Phase 2 Not yet recruiting

84 enrolled

Small Cell Lung Carcinoma

NCT03138720 2026-04-22

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

Phase 2 Completed

40 enrolled 22 charts

Resectable Pancreatic Cancer

NCT06423326 2026-04-22

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

36 enrolled

Pancreatic Neoplasms

NCT02957968 2026-04-21

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

46 enrolled 21 charts

Phase 3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05771480 2026-04-21

TOURMALINE

142 enrolled

Biliary Tract Neoplasms

NCT06743126 2026-04-21

SUPRAME

770 enrolled 13 charts 1 FDA

360 enrolled

Dermatologic

Melanoma, Cutaneous Malignant

NCT04083235 2026-04-20

NAPOLI 3

Phase 3 Completed

Metastatic Adenocarcinoma of the Pancreas

NCT05632328 2026-04-20

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

24 enrolled

Pancreatic Neoplasms

NCT06447662 2026-04-20

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Phase 1 Recruiting

330 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT04158635 2026-04-17

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Phase 1 Recruiting

21 enrolled

Pancreatic Neoplasms

NCT06492759 2026-04-17

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Triple Negative Breast Neoplasms

NCT04940286 2026-04-16

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

13 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT05497778 2026-04-16

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

19 enrolled

Pancreatic Neoplasms

NCT07530445 2026-04-15

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

40 enrolled